Who Paid My Doc
Joseph Murray
Psychiatry New York, NY Medical Doctor
NPI 1003960014 CMS profile 875660
119 W 24Th St, Ground Floor, New York, NY 10011
General payments
$32
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Joseph Murray of New York, NY is reported in the CMS Open Payments database as having received $32 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 13th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $32 | 1 |
Beside peers
- Joseph Murray
- Psychiatry median
- Middle half of Psychiatry
- National median
In program year 2025, general payments to Joseph Murray were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.
Show as a table
| Year | Joseph Murray | Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $184 | $59–$605 | $163 |
| 2020 | $32 | $119 | $36–$372 | $114 |
| 2021 | $0 | $143 | $43–$576 | $132 |
| 2022 | $0 | $153 | $50–$590 | $149 |
| 2023 | $0 | $170 | $56–$651 | $160 |
| 2024 | $0 | $179 | $57–$673 | $164 |
| 2025 | $0 | $180 | $58–$685 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 47 drugsPart D claims
1,869
Drug cost
$125,668
Branded share of claims
28.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Austedo Deutetrabenazine | Brand | 13 | $59,563 | |
| Emsam Selegiline | Brand | 12 | $23,995 | |
| Adderall Xr Dextroamphetamine/Amphetamine | Brand | 41 | $8,258 | |
| Bupropion Xl Bupropion Hcl | Brand | 172 | $3,977 | |
| Viibryd Vilazodone Hcl | Brand | 11 | $3,417 | |
| Zolpidem Tartrate Er Zolpidem Tartrate | Brand | 22 | $2,282 | |
| Ramelteon | Generic | 27 | $2,201 | |
| Eszopiclone | Generic | 12 | $1,586 | |
| Duloxetine Hcl | Generic | 90 | $1,479 | |
| Lurasidone Hcl | Generic | 37 | $1,396 |
The 10 drugs with the highest cost, of 47 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Psychiatry in New York
Related records
Psychiatry in New York
Practitioners in the same specialty and state, ranked by reported value.
All Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.